The CCL21-dendritic vaccine was directly applied to the tumors of 16 patients with NSCLC, and at day 56, 25% of the patients had stable disease (meaning their tumors did not increase or decrease in size). The gene discussed is CCL21; the disease is non-small cell lung carcinoma.